{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:01:34Z","timestamp":1782601294944,"version":"3.54.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,11,27]],"date-time":"2014-11-27T00:00:00Z","timestamp":1417046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2014,11,27]],"date-time":"2014-11-27T00:00:00Z","timestamp":1417046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>In clinical practice, nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly discontinued after response to biologic therapy is achieved in patients with axial spondyloarthritis (axSpA), but the impact of NSAID discontinuation has not been assessed in prospective controlled trials. The aim of the SPARSE study was to evaluate the effects of the anti-tumor necrosis factor agent etanercept on NSAID intake and conventional clinical outcomes in axSpA patients.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>In the double-blind, placebo-controlled period, patients with active (mini Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) \u22654) axSpA despite optimal NSAID intake were randomized to receive etanercept 50\u00a0mg or placebo once weekly for 8\u00a0weeks. All patients were advised to taper\/discontinue their NSAID intake during the treatment period. NSAID intake was self-reported by diary and Assessment of SpondyloArthritis International Society (ASAS)-NSAID scores calculated based on ASAS recommendations. The primary endpoint was change from baseline to week 8 in ASAS-NSAID score (analysis of covariance).<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>In 90 randomized patients at baseline, mean age (standard deviation) was 38.9 (11.8) years; disease duration, 5.7 (8.1) years; 59\/90 (66%) were human leukocyte antigen-B27 positive; 51\/90 (57%) had radiographic sacroiliitis; and 45\/90 (50%) were magnetic resonance imaging sacroiliitis-positive. Mean ASAS-NSAID scores were similar between etanercept and placebo groups at baseline (98.2 (39.0) versus 93.0 (23.4)), as were BASDAI (6.0 (1.7) versus 5.9 (1.5)), and Bath Ankylosing Spondylitis Functional Index (5.2 (2.1) versus 5.1 (2.2)). Mean changes (SE) in ASAS-NSAID score from baseline to week 8 were \u201363.9 (6.1) and \u201336.6 (5.9) in the etanercept and placebo groups (between-group difference, \u201327.3; <jats:italic>P<\/jats:italic>\u2009=\u20090.002). Significantly higher proportions of patients receiving etanercept versus placebo had an ASAS-NSAID score &lt;10 (46% versus 17%; <jats:italic>P<\/jats:italic>\u2009=\u20090.008) and ASAS-NSAID score of 0 (41% versus 14%; <jats:italic>P<\/jats:italic>\u2009=\u20090.013) at this time point. Significantly more patients in the etanercept versus placebo group achieved BASDAI50 (39% versus 18%; <jats:italic>P<\/jats:italic>\u2009=\u20090.032) and ASAS40 (44% versus 21%; <jats:italic>P<\/jats:italic>\u2009=\u20090.028) at week 8.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>In patients with axSpA, etanercept was associated with clinically relevant NSAID-sparing effects in addition to significant improvements in conventional clinical outcomes.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Trial registration<\/jats:title>\n                        <jats:p>ClinicalTrials.gov <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01298531\">NCT01298531<\/jats:ext-link>. Registered 16 February 2011.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/s13075-014-0481-5","type":"journal-article","created":{"date-parts":[[2014,11,27]],"date-time":"2014-11-27T02:03:16Z","timestamp":1417053796000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study"],"prefix":"10.1186","volume":"16","author":[{"given":"Maxime","family":"Dougados","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Combe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Schaeverbeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Miceli-Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Berenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandan","family":"Koppiker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Dubanchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Logeart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,27]]},"reference":[{"key":"481_CR1","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","volume":"377","author":"M Dougados","year":"2011","unstructured":"Dougados M, Baeten D: Spondyloarthritis. Lancet. 2011, 377: 2127-2137. 10.1016\/S0140-6736(11)60071-8.","journal-title":"Lancet"},{"key":"481_CR2","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, S\u00f8rensen IJ, Ozgocmen S, Roussou E, Valle-O\u00f1ate R, Weber U, Wei J, Sieper J: The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009, 68: 777-783. 10.1136\/ard.2009.108233.","journal-title":"Ann Rheum Dis"},{"key":"481_CR3","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/art.24483","volume":"60","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Haibel H, Baraliakos X, Listing J, Marker-Hermann E, Zeidler H, Braun J, Sieper J: The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum. 2009, 60: 717-727. 10.1002\/art.24483.","journal-title":"Arthritis Rheum"},{"key":"481_CR4","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1002\/acr.21688","volume":"64","author":"U Kiltz","year":"2012","unstructured":"Kiltz U, Baraliakos X, Karakostas P, Igelmann M, Kalthoff L, Klink C, Krause D, Schmitz-Bortz E, Florecke M, Bollow M, Braun J: Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis?. Arthritis Care Res. 2012, 64: 1415-1422. 10.1002\/acr.21688.","journal-title":"Arthritis Care Res"},{"key":"481_CR5","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1002\/art.38140","volume":"65","author":"A Ciurea","year":"2013","unstructured":"Ciurea A, Scherer A, Exer P, Bernhard J, Dudler J, Beyeler B, Kissling R, Stekhoven D, Rufibach K, Tamborrini G, Weiss B, M\u00fcller R, Nissen MJ, Michel BA, van der Heijde D, Dougados M, Boonen A, Weber U: Tumor necrosis factor alpha inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort. Arthritis Rheum. 2013, 65: 3096-3106. 10.1002\/art.38140.","journal-title":"Arthritis Rheum"},{"key":"481_CR6","doi-asserted-by":"publisher","first-page":"iii40","DOI":"10.1136\/ard.61.suppl_3.iii40","volume":"61","author":"M Dougados","year":"2002","unstructured":"Dougados M, Dijkmans B, Khan M, Maksymowych W, van der Linden S, Brandt J: Conventional treatments for ankylosing spondylitis. Ann Rheum Dis. 2002, 61: iii40-iii50. 10.1136\/ard.61.suppl_3.iii40.","journal-title":"Ann Rheum Dis"},{"key":"481_CR7","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, Dagfinrud H, Dijkmans B, Dougados M, Emery P, Geher P, Hammoudeh M, Inman RD, Jongkees M, Khan MA, Kiltz U, Kvien T, Leirisalo-Repo M, Maksymowych WP, Olivieri I, Pavelka K, Sieper J, Stanislawska-Biernat E, Wendling D, Ozgocmen S, van Drogen C, van Royen B, van der Heijde D: 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011, 70: 896-904. 10.1136\/ard.2011.151027.","journal-title":"Ann Rheum Dis"},{"key":"481_CR8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/rheumatology\/38.3.235","volume":"38","author":"M Dougados","year":"1999","unstructured":"Dougados M, Gueguen A, Nakache JP, Velicitat P, Veys EM, Zeidler H, Calin A: Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6\u00a0weeks non-steroidal anti-inflammatory drug trial. Rheumatology (Oxford). 1999, 38: 235-244. 10.1093\/rheumatology\/38.3.235.","journal-title":"Rheumatology (Oxford)"},{"key":"481_CR9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K","volume":"44","author":"M Dougados","year":"2001","unstructured":"Dougados M, Behier JM, Jolchine I, Calin A, van der Heijde D, Olivieri I, Zeidler H, Herman H: Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum. 2001, 44: 180-185. 10.1002\/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K.","journal-title":"Arthritis Rheum"},{"key":"481_CR10","first-page":"S65","volume":"20","author":"C Miceli-Richard","year":"2002","unstructured":"Miceli-Richard C, Dougados M: NSAIDs in ankylosing spondylitis. Clin Exp Rheumatol. 2002, 20: S65-S66.","journal-title":"Clin Exp Rheumatol"},{"key":"481_CR11","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1093\/rheumatology\/kep393","volume":"49","author":"M Benhamou","year":"2010","unstructured":"Benhamou M, Gossec L, Dougados M: Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs\/coxibs\u2019 treatment effect on C-reactive protein. Rheumatology (Oxford). 2010, 49: 536-541. 10.1093\/rheumatology\/kep393.","journal-title":"Rheumatology (Oxford)"},{"key":"481_CR12","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/art.21054","volume":"52","author":"A Wanders","year":"2005","unstructured":"Wanders A, Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, Zeidler H, Dougados M: Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005, 52: 1756-1765. 10.1002\/art.21054.","journal-title":"Arthritis Rheum"},{"key":"481_CR13","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1136\/annrheumdis-2012-201370","volume":"71","author":"F Kroon","year":"2012","unstructured":"Kroon F, Landewe R, Dougados M, van der Heijde D: Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis. 2012, 71: 1623-1629. 10.1136\/annrheumdis-2012-201370.","journal-title":"Ann Rheum Dis"},{"key":"481_CR14","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1136\/annrheumdis-2011-201252","volume":"71","author":"D Poddubnyy","year":"2012","unstructured":"Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-Hermann E, Zeidler H, Braun J, Sieper J: Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis. 2012, 71: 1616-1622. 10.1136\/annrheumdis-2011-201252.","journal-title":"Ann Rheum Dis"},{"key":"481_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1471-230X-9-41","volume":"9","author":"S Straube","year":"2009","unstructured":"Straube S, Tramer MR, Moore RA, Derry S, McQuay HJ: Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. BMC Gastroenterol. 2009, 9: 41-10.1186\/1471-230X-9-41.","journal-title":"BMC Gastroenterol"},{"key":"481_CR16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1136\/ard.2006.055012","volume":"66","author":"M Boers","year":"2007","unstructured":"Boers M, Tangelder MJ, van Ingen H, Fort JG, Goldstein JL: The rate of NSAID-induced endoscopic ulcers increases linearly but not exponentially with age: a pooled analysis of 12 randomised trials. Ann Rheum Dis. 2007, 66: 417-418. 10.1136\/ard.2006.055012.","journal-title":"Ann Rheum Dis"},{"key":"481_CR17","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/ard.2006.068650","volume":"66","author":"PA Scott","year":"2007","unstructured":"Scott PA, Kingsley GH, Smith CM, Choy EH, Scott DL: Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis. 2007, 66: 1296-1304. 10.1136\/ard.2006.068650.","journal-title":"Ann Rheum Dis"},{"key":"481_CR18","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.amjcard.2009.01.014","volume":"103","author":"ME Farkouh","year":"2009","unstructured":"Farkouh ME, Greenberg BP: An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol. 2009, 103: 1227-1237. 10.1016\/j.amjcard.2009.01.014.","journal-title":"Am J Cardiol"},{"key":"481_CR19","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1093\/aje\/kwj331","volume":"164","author":"V Schneider","year":"2006","unstructured":"Schneider V, Levesque LE, Zhang B, Hutchinson T, Brophy JM: Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis. Am J Epidemiol. 2006, 164: 881-889. 10.1093\/aje\/kwj331.","journal-title":"Am J Epidemiol"},{"key":"481_CR20","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1001\/archinte.163.22.2716","volume":"163","author":"DM Fick","year":"2003","unstructured":"Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH: Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003, 163: 2716-2724. 10.1001\/archinte.163.22.2716.","journal-title":"Arch Intern Med"},{"key":"481_CR21","unstructured":"Rappel des r\u00e8gles de bon usage des AINS. [http:\/\/ansm.sante.fr\/var\/ansm_site\/storage\/original\/application\/257d8be960ac8372dbdc513708956d50.pdf]"},{"key":"481_CR22","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/art.30223","volume":"63","author":"J Braun","year":"2010","unstructured":"Braun J, van der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, Vlahos B, Koenig AS, Freundlich B: Clinical efficacy and safety of etanercept versus sulfasalazine in ankylosing spondylitis patients: a randomized, double-blind study (ASCEND Trial). Arthritis Rheum. 2010, 63: 1543-1551. 10.1002\/art.30223.","journal-title":"Arthritis Rheum"},{"key":"481_CR23","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis Jr","year":"2003","unstructured":"Davis JC, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W: Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003, 48: 3230-3236. 10.1002\/art.11325.","journal-title":"Arthritis Rheum"},{"key":"481_CR24","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC: Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006, 54: 2136-2146. 10.1002\/art.21913.","journal-title":"Arthritis Rheum"},{"key":"481_CR25","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1136\/ard.2007.075879","volume":"67","author":"J Braun","year":"2008","unstructured":"Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, Krause A, Schewe S, Schneider M, Sorensen H, Zeidler H, Sieper J: Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5\u00a0years: evidence for different types of response. Ann Rheum Dis. 2008, 67: 340-345. 10.1136\/ard.2007.075879.","journal-title":"Ann Rheum Dis"},{"key":"481_CR26","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, Arora V, Pangan AL: Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013, 72: 815-822. 10.1136\/annrheumdis-2012-201766.","journal-title":"Ann Rheum Dis"},{"key":"481_CR27","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1136\/annrheumdis-2012-202389","volume":"72","author":"IH Song","year":"2013","unstructured":"Song IH, Weiss A, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, Lange E, Freundlich B, Rudwaleit M, Sieper J: Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1\u00a0year of treatment with etanercept: results from the ESTHER trial. Ann Rheum Dis. 2013, 72: 823-825. 10.1136\/annrheumdis-2012-202389.","journal-title":"Ann Rheum Dis"},{"key":"481_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","volume":"73","author":"R Landewe","year":"2014","unstructured":"Landewe R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, Reveille JD, Rudwaleit M, van der Heijde D, Stach C, Hoepken B, Fichtner A, Coteur G, de Longueville M, Sieper J: Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study. Ann Rheum Dis. 2014, 73: 39-47. 10.1136\/annrheumdis-2013-204231.","journal-title":"Ann Rheum Dis"},{"key":"481_CR29","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","volume":"65","author":"N Haroon","year":"2013","unstructured":"Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH, Ward MM, Reveille JD, Gensler LS: The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013, 65: 2645-2654.","journal-title":"Arthritis Rheum"},{"key":"481_CR30","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1002\/art.38613","volume":"66","author":"A Molto","year":"2014","unstructured":"Molto A, Paternotte S, Claudepierre P, Breban M, Dougados M: Effectiveness of tumor necrosis factor alpha blockers in early axial spondyloarthritis: data from the DESIR cohort. Arthritis Rheumatol. 2014, 66: 1734-1744. 10.1002\/art.38613.","journal-title":"Arthritis Rheumatol"},{"key":"481_CR31","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1136\/ard.2010.133488","volume":"70","author":"M Dougados","year":"2011","unstructured":"Dougados M, Simon P, Braun J, Burgos-Vargas R, Maksymowych WP, Sieper J, van der Heijde D: ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials\/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis. 2011, 70: 249-251. 10.1136\/ard.2010.133488.","journal-title":"Ann Rheum Dis"},{"key":"481_CR32","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A: A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994, 21: 2286-2291.","journal-title":"J Rheumatol"},{"key":"481_CR33","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1136\/ard.2008.099226","volume":"68","author":"IH Song","year":"2009","unstructured":"Song IH, Rudwaleit M, Listing J, Sieper J: Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations. Ann Rheum Dis. 2009, 68: 1701-1707. 10.1136\/ard.2008.099226.","journal-title":"Ann Rheum Dis"},{"key":"481_CR34","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1136\/annrheumdis-2011-201038","volume":"71","author":"M Dougados","year":"2012","unstructured":"Dougados M, Braun J, Vargas RB, Gossec L, Maksymowych W, Sieper J, van der Heijde D: ASAS recommendations for variables to be collected in clinical trials\/epidemiological studies of spondyloarthritis. Ann Rheum Dis. 2012, 71: 1103-1104. 10.1136\/annrheumdis-2011-201038.","journal-title":"Ann Rheum Dis"},{"key":"481_CR35","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","volume":"44","author":"JJ Anderson","year":"2001","unstructured":"Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M: Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001, 44: 1876-1886. 10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F.","journal-title":"Arthritis Rheum"},{"key":"481_CR36","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/art.20790","volume":"52","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde D, Dougados M, Davis J, Weisman MH, Maksymowych W, Braun J, Hallegua DS, Bruckel J: ASsessment in Ankylosing Spondylitis International Working Group\/Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitis. Arthritis Rheum. 2005, 52: 386-394. 10.1002\/art.20790.","journal-title":"Arthritis Rheum"},{"key":"481_CR37","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/art.22342","volume":"55","author":"F Tubach","year":"2006","unstructured":"Tubach F, Pham T, Skomsvoll JF, Mikkelsen K, Bjorneboe O, Ravaud P, Dougados M, Kvien TK: Stability of the patient acceptable symptomatic state over time in outcome criteria in ankylosing spondylitis. Arthritis Rheum. 2006, 55: 960-963. 10.1002\/art.22342.","journal-title":"Arthritis Rheum"},{"key":"481_CR38","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/art.23527","volume":"59","author":"M Dougados","year":"2008","unstructured":"Dougados M, Luo MP, Maksymowych WP, Chmiel JJ, Chen N, Wong RL, Davis JC, van der Heijde D: Evaluation of the patient acceptable symptom state as an outcome measure in patients with ankylosing spondylitis: data from a randomized controlled trial. Arthritis Rheum. 2008, 59: 553-560. 10.1002\/art.23527.","journal-title":"Arthritis Rheum"},{"key":"481_CR39","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1136\/ard.2008.100826","volume":"68","author":"D van der Heijde","year":"2009","unstructured":"van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, Braun J, Landewe R: ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009, 68: 1811-1818. 10.1136\/ard.2008.100826.","journal-title":"Ann Rheum Dis"},{"key":"481_CR40","first-page":"2281","volume":"21","author":"A Calin","year":"1994","unstructured":"Calin A, Garrett S, Whitelock H, Kennedy LG, O\u2019Hea J, Mallorie P, Jenkinson T: A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994, 21: 2281-2285.","journal-title":"J Rheumatol"},{"key":"481_CR41","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984, 27: 361-368. 10.1002\/art.1780270401.","journal-title":"Arthritis Rheum"},{"key":"481_CR42","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1136\/ard.2009.110767","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Jurik AG, Hermann KG, Landewe R, van der Heijde D, Baraliakos X, Marzo-Ortega H, Ostergaard M, Braun J, Sieper J: Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS\/OMERACT MRI group. Ann Rheum Dis. 2009, 68: 1520-1527. 10.1136\/ard.2009.110767.","journal-title":"Ann Rheum Dis"},{"key":"481_CR43","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/acr.20671","volume":"64","author":"M Dougados","year":"2012","unstructured":"Dougados M, Braun J, Szanto S, Combe B, Geher P, Leblanc V, Logeart I: Nonsteroidal antiinflammatory drug intake according to the Assessment of SpondyloArthritis International Society Score in clinical trials evaluating tumor necrosis factor blockers: example of etanercept in advanced ankylosing spondylitis. Arthritis Care Res. 2012, 64: 290-294. 10.1002\/acr.20671.","journal-title":"Arthritis Care Res"},{"key":"481_CR44","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1136\/ard.2010.139261","volume":"70","author":"M Dougados","year":"2011","unstructured":"Dougados M, Braun J, Szanto S, Combe B, Elbaz M, Geher P, Thabut G, Leblanc V, Logeart I: Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis. 2011, 70: 799-804. 10.1136\/ard.2010.139261.","journal-title":"Ann Rheum Dis"},{"key":"481_CR45","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/rheumatology\/kes142","volume":"51","author":"D van der Heijde","year":"2012","unstructured":"van der Heijde D, Braun J, Dougados M, Sieper J, Pedersen R, Szumski A, Koenig AS: Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial. Rheumatology (Oxford). 2012, 51: 1894-1905. 10.1093\/rheumatology\/kes142.","journal-title":"Rheumatology (Oxford)"},{"key":"481_CR46","first-page":"905","volume":"2011","author":"D van der Heijde","year":"2010","unstructured":"van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewe R, Rudwaleit M, Braun J: Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2010, 2011: 905-908.","journal-title":"Ann Rheum Dis"},{"key":"481_CR47","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1136\/annrheumdis-2012-203148","volume":"72","author":"D Poddubnyy","year":"2013","unstructured":"Poddubnyy D, Haibel H, Listing J, Marker-Hermann E, Zeidler H, Braun J, Sieper J, Rudwaleit M: Cigarette smoking has a dose-dependent impact on progression of structural damage in the spine in patients with axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort (GESPIC). Ann Rheum Dis. 2013, 72: 1430-1432. 10.1136\/annrheumdis-2012-203148.","journal-title":"Ann Rheum Dis"},{"key":"481_CR48","volume-title":"Annals of the Rheumatic Diseases","author":"A Molto","year":"2014","unstructured":"Molto A, Paternotte S, van der Heijde D, Claudepierre P, Rudwaleit M, Dougados M: Evaluation of the validity of the different arms of the ASAS set of criteria for axial spondyloarthritis and description of the different imaging abnormalities suggestive of spondyloarthritis: data from the DESIR cohort. In Annals of the Rheumatic Diseases. 2014\/01\/07th edition; 2014.","edition":"2014\/01\/07"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-014-0481-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-014-0481-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-014-0481-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-014-0481-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T16:26:04Z","timestamp":1728923164000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-014-0481-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,27]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,12]]}},"alternative-id":["481"],"URL":"https:\/\/doi.org\/10.1186\/s13075-014-0481-5","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,27]]},"assertion":[{"value":"8 June 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"481"}}